Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Caris Life Sciences Inc (NASDAQ: CAI) closed the day trading at $36.8 up 0.66% from the previous closing price of $36.56. In other words, the price has increased by $0.66 from its previous closing price. On the day, 0.69 million shares were traded. CAI stock price reached its highest trading level at $37.42 during the session, while it also had its lowest trading level at $35.815.
Ratios:
For a better understanding of CAI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.79 and its Current Ratio is at 9.24. In the meantime, Its Debt-to-Equity ratio is 0.93 whereas as Long-Term Debt/Eq ratio is at 0.91.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on July 14, 2025, initiated with a Outperform rating and assigned the stock a target price of $32.
On July 14, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $32.
On July 14, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $31.JP Morgan initiated its Overweight rating on July 14, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 20 ’25 when Denton John Russel bought 7,500 shares for $21.00 per share. The transaction valued at 157,500 led to the insider holds 123,591 shares of the business.
Brille Brian J bought 30,000 shares of CAI for $630,000 on Jun 20 ’25. The insider now owns 162,428 shares after completing the transaction at $21.00 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAI now has a Market Capitalization of 10350662656 and an Enterprise Value of 10046844928. Its current Enterprise Value per Revenue stands at 18.82 whereas that against EBITDA is -71.368.
Stock Price History:
Over the past 52 weeks, CAI has reached a high of $42.50, while it has fallen to a 52-week low of $25.40. The 50-Day Moving Average of the stock is 18.51%, while the 200-Day Moving Average is calculated to be 19.37%.
Shares Statistics:
Over the past 3-months, CAI traded about 1.07M shares per day on average, while over the past 10 days, CAI traded about 528670 shares per day. A total of 281.09M shares are outstanding, with a floating share count of 92.16M. Insiders hold about 67.23% of the company’s shares, while institutions hold 35.91% stake in the company. Shares short for CAI as of 1755216000 were 1733651 with a Short Ratio of 1.63, compared to 1752537600 on 1565776. Therefore, it implies a Short% of Shares Outstanding of 1733651 and a Short% of Float of 1.2.
Earnings Estimates
Caris Life Sciences Inc (CAI) is presently subject to a detailed evaluation by 6 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.02, with high estimates of $0.08 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.85 and -$8.86 for the fiscal current year, implying an average EPS of -$2.52. EPS for the following year is $0.26, with 6.0 analysts recommending between $0.49 and -$0.05.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $205.37M. There is a high estimate of $214M for the next quarter, whereas the lowest estimate is $200.01M.
Based on 8 analysts’ estimates, the company’s revenue will be $977.6M in the next fiscal year. The high estimate is $1.01B and the low estimate is $955.4M.
